Varenicline for smoking cessation

TA123 Smoking cessation - varenicline: review decision - January 2011 information

TA123 Smoking cessation - varenicline: appendix A: review decision paper considered by the Institute's Guidance Executive (PDF 87 KB)

Review Proposal - October 2010 information

Appendix A: provisional matrix of stakeholders (MSWord 70 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 193 KB)

Final appraisal determination information

Final appraisal determination (PDF 108 KB)

Evaluation report

Non-manufacturer submissions

British Cardiovascular Society (PDF 37 KB)

East Lancashire PCT (PDF 41 KB)

General Practice Airways Group (PDF 52 KB)

General Practice Airways Group supporting document (PDF 76 KB)

Roy Castle Lung Cancer Foundation (PDF 78 KB)

Manufacturer submission (PDF 1.42 MB)

Clarification letters

NICE clarification letter 1 (PDF 29 KB)

NICE clarification letter 2 (PDF 17 KB)

Pfizer clarification letter (PDF 578 KB)

Pre-meeting briefing (PDF 53 KB)

Expert written personal statements

Geldard (PDF 38 KB)

Owens (PDF 77 KB)

Smoking cessation - varenicline: evidence review group report (PDF 475 KB)

Smoking cessation - varenicline: Final scope (PDF 37 KB)

Smoking cessation - varenicline: Response to consultee and commentator comments on the draft scope (PDF 113 KB)

Smoking cessation - varenicline: Response to consultee and commentator comments on the provisional matrix of consultees and commentators (PDF 24 KB)

Smoking cessation - varenicline: Audit criteria (PDF 146 KB)